This alteration improves the tumor immune microenvironment and facilitates the transformation of “cold tumors” into “hot tumors”, thereby enhancing the efficacy of PD-1/PD-L1 checkpoint inhibitors [152]. Here, PDCD1 is linked to neoplasm.